## LIVER-BRAIN UNIT «RITA MORETTI»





- Parkinson's disease
- Early mechanisms
- Prevention life stile
- Kernicterus
- Autism spectrum disorder
- Schizophrenia
- Attention deficit hyperactivity disorder



### Neurological disorders



#### Affect all life-ages


Ranked (2016) as the leading cause of disability-adjusted life-years (276 million) and the second leading cause of death (9.0 million, comprising of 16.5% of global deaths).


Neurological disorders burden has increased substantially in the past two to three decades.

Mostly due to the ageing of the world-wild population, the lack of cures, and, at least in part, the limited efficacy of prophylactic measures.

Strong association exists between neurocognitive disorders at all ages and early-life adversity.







#### Parkinson disease (PD)



The 2<sup>nd</sup> most common neurodegenerative disorder; estimated to be a noninfectious pandemic in 2040



Bradykinesia, rest tremor, and rigidity are still remained as the core of Parkinson's disease diagnosis, that is actually reached late (40-50%





Still relies on symptomatic treatments (after diagnosis); no diseasemodifying therapy available




Prophylactic approach

Stop-delaying approach










Fondazione Italiana Fegato ONLUS





Time sco

## **Prophylactic approach:**

- Development of a slow progressing in vitro PD model for screening large # of drugs
- ✓ <u>Drug-transcriptomics (target validation)</u>
- Selection of candidates for safety/efficacy evaluation in complex models

**Stop delaying progression therapy:** 



Fondazione Italiana Fegato ONLUS

# To date about Parkinson's disease



The 2<sup>nd</sup> most common neurodegenerative disorder Estimated to be a noninfectious pandemic in 2040



Bradykinesia, rest tremor, and rigidity are still remained as the core of PD diagnosis, that is actually reached late



No specific biomarker available





Still relies on symptomatic treaements
No disease-modifying therapy

